Skylar Jeremias

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Biosimilars Oncology Roundup for June 2024—Podcast Edition

July 07, 2024

Podcast

On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.

Eye on Pharma: New Data, Clinical Developments, and Biosimilar Partnerships

July 04, 2024

Article

As Celltrion publishes phase 3 data on its tocilizumab biosimilar, other companies finalize partnerships, and Formycon begins development for a pembrolizumab biosimilar.

Biosimilars Oncology Roundup: June 2024

July 02, 2024

Article

As the weather heats up for the US and Europe, so too did the biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.

Ahzantive Receives FDA Approval as New Eylea Biosimilar

July 01, 2024

Article

The FDA has approved Ahzantive (aflibercept-mrbb) as the third biosimilar referencing Eylea (aflibercept) for the treatment of eye conditions, including age-related macular degeneration.

FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara

July 01, 2024

Article

Pyzchiva (ustekinumab-ttwe) is the third ustekinumab biosimilar to receive approval for the American market. It was also approved with interchangeability.

EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions

June 27, 2024

Article

Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.

Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching

June 26, 2024

Article

Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.

Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability

June 25, 2024

Article

Authors of a commentary piece propose solutions to sustainability issues for biosimilar markets and shed light on common sustainability challenges global markets face.

ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars

June 24, 2024

Article

Two posters from the American Society of Clinical Oncology (ASCO) annual meeting look at Medicare reimbursement trends for originator and biosimilar biologics, as well as a combination therapy utilizing a pegfilgrastim biosimilar in patients with advanced hepatocellular carcinoma.

FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability

June 20, 2024

Article

The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.